^
Association details:
| Biomarker: | ALK A348D |
|---|---|
| Cancer: | Leukemia |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutically targetable ALK mutations in leukemia
Excerpt:
The growth of Ba/F3 cells expressing both mutants was highly sensitive to crizotinib, with IC50s of 33 nM for ALK A348D cells and 6 nM for the ALK F856S cells (Figure 2D).
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576
